Mahmoud A. Ghannoum, PhD

Mahmoud Ghannoum, PhD is a tenured Professor and Director of the Center for Medical Mycology at Case Western Reserve University and University Hospitals Medical Center.

He is also the co-founder of BIOHM Health, one of the leading consumer microbiome companies in the United States.

He is also the founder of NTS Ventures, one of the leading microbiome and fungal clinical research organizations globally.

He is a Fellow of the Infectious Disease Society of America, and served as a President of the Medical Mycological Society of the Americas. He received the Freedom to Discover Award from Bristol-Myers Squibb for his expertise in the field of fungal biofilms, and the Billy Cooper Award from the Mycological Societies of the Americas for his contribution to the field of clinical mycology.

He has published over 400 peer-reviewed articles in the field of biofilms, the microbiome, microbial pathogenesis and preclinical in vitro and in vivo evaluations of antimicrobials. He also published the first study describing the oral mycobiome of healthy individuals, and the interaction between bacteria and fungi in the microbiomes of Crohn's patients. His work has been cited over 19,000 times in the medical literature.

In 2009, he was appointed as the Chairman of the Subcommittee on Antifungal Susceptibility Testing, Clinical Laboratory Standards Institute. In 2013, he was appointed as an Advisor to the CLSI Consensus Microbiology Committee. Dr. Ghannoum has been involved in preclinical and clinical studies evaluating the efficacy of antifungals.

He has acted as a consultant for pharmaceutical/Biotech industry and serve on advisory boards for various sponsors where he provide guidance regarding strategies for development of their potential anti-infectives that is in concordance with regulatory bodies.